Recent studies reported that PPAR-γ is associated with the modulation of inflammation in fatty-liver disease and is involved in the development of hepatic steatosis by controlling fatty-acid transport, and a PPAR-γ agonist treatment prevents alcoholic liver injury in rats [43,44,45]. The gene discussed is PPARG; the disease is Hepatic steatosis.